Feel the Rhythmia—Entrepreneurs & VCs Plan for Mega-Return

Boston Scientific, the listed medical device company, announced it will spend $90 million up front and as much as a whopping $175 million more in milestone payments over the next five years to acquire Rhythmia Medical, a Massachusetts startup treats cardiac arrhythmia. And, paid in full, that will result in a whopping exit of more than 16x for VCs and entrepreneurs who dedicated their last eight years and about $16.5 million to the company.

North AmericaUS